Trial · NCT07557498
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 24 of 24
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to mavacamten treatment resumption | Baseline, and at weeks 4, 8, 12, 24 | Group 1 only |
| Primary | Type of hypertrophic cardiomyopathy (HCM) background therapy prescribed | Baseline, and at weeks 4, 8, 12, 24 | Group 1 only |
| Primary | Type of changes to hypertrophic cardiomyopathy (HCM) background therapy | At baseline, weeks 4, 8, 12, 24 | Group 1 only. Type of changes include initiation, switching, discontinuation, augmentation, dose titration |
| Secondary | Perspectives on treatment preference, and the eligibility, onboarding and implementation of mavacamten as assessed by feedback collated through structured physician interviews | Up to week 24 | Group 2 only |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07557498/registered?page=2